Comment: Advances in breast cancer presented at ASCO 2014

Ramucirumab plus docetaxel extends survival in advanced NSCLC

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

Cancer evasion of the immune system: the fundamentals

Checkpoint blockade: a concept or already a reality?

Emerging pathways in immunotherapy

New rules for clinical trials